HUTCHMED (China) Limited HCM
15.38 USD +0.06 (+0.39%)
At closeNov 11, 2026, 4:12 AM EST
15.30 -0.08 -0.52%
Pre-market · Nov 11, 4:12 AM ET
15.29 Day range 15.48
9.77 52-week range 16.33
- YTD
- +15.38%
- 1 year
- +1.92%
News
globenewswire.com Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen…
prnewswire.com Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring – Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two…
benzinga.com Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent…
globenewswire.com HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia — Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
benzinga.com Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
benzinga.com HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned — ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…- benzinga.com HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…